AtaiBeckley (ATAI) Capital Expenditures (2020 - 2025)

AtaiBeckley's (ATAI) quarterly Capital Expenditures came in at $268000.0 in Q1 2025.

AtaiBeckley (ATAI) Capital Expenditures (2020 - 2025) Analysis & Trends

AtaiBeckley (ATAI) has 6 years of Capital Expenditures data on file, last reported at $396000.0 in Q3 2025.

For the quarter ending Q3 2025, Capital Expenditures rose 6500.0% year-over-year to $396000.0; the trailing twelve-month figure through Sep 2025 stood at $791000.0 (up 819.77% YoY), and the FY2024 full-year result was $6000.0, down 98.19% from the prior year.
Capital Expenditures steadied at $268000.0 in Q1 2025 per ATAI's latest filing.
In the past five years, Capital Expenditures ranged from a high of $459000.0 in Q3 2022 to a low of -$100000.0 in Q4 2021.
A 5-year average of $129625.0 and a median of $98000.0 in 2022 frame the typical range for Capital Expenditures.
Peak annual rise in Capital Expenditures reached 7700.0% in 2021, while the deepest fall reached 300.0% in 2021.
Tracing ATAI's Capital Expenditures over 5 years: stood at -$100000.0 in 2021, then jumped by 242.0% to $142000.0 in 2022, then slumped by 43.66% to $80000.0 in 2023, then sank by 92.5% to $6000.0 in 2024, then soared by 6500.0% to $396000.0 in 2025.
Business Quant data shows ATAI's Capital Expenditures at $396000.0 in Q3 2025, $127000.0 in Q2 2025, and $268000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	AtaiBeckley	2.56 Bn	2.56 Bn	-	396,000.00

Download Data